Endocrine Abstracts

Aims/objectives: Obesity and prediabetes are risk factors for developing T2D. 5–10% weight-loss can reduce risk of developing T2D by >50%. The 3-year part of this phase 3 trial investigated effects of liraglutide 3.0 mg, as adjunct to diet+exercise, in delaying onset of T2D over 3 years, body-weight and cardiometabolic risk factors in adults with obesity or overweight with comorbidities, and diagnosed with prediabetes at screening.Methods: Indiv...

Background: The 3-year part of this trial investigated the effect of liraglutide 3.0 mg, as an adjunct to diet+exercise, in delaying onset of T2D (primary endpoint) in adults with prediabetes and obesity (BMI ≥30 kg/m2) or overweight (≥27 kg/m2) with comorbidities.Methods: Participants were randomised 2:1 to once-daily subcutaneous liraglutide 3.0 mg or placebo plus 500 kcal/day deficit diet and 150...

Introduction: Methods to predict clinically meaningful weight loss can help tailor treatment for people with overweight or obesity. LIGHT-UP (NCT03058029), is a multicenter, double-blind, randomized, placebo-controlled study over 25 weeks including 254 people with prediabetes or type 2 diabetes (127 each in the Gelesis200 and placebo arms) with a body mass index between 27 and 40 kg/m2, which demonstrated that Gelesis200 offers a compelling new potential approach in...

Introduction: Identification of early responders is widely used in pharmacotherapy for weight loss to minimize unnecessary exposure to risks and unnecessary expenses. Gelesis Loss Of Weight (GLOW; NCT02307279), a multicenter, double-blind, placebo-controlled pivotal study, demonstrated that Gelesis100 offers a compelling new potential approach in the management of overweight and obesity.Objective: A post-hoc area under the curve (AUC) for the receiver op...